Highlights from Cereno Scientific’s Capital Markets Day 2026 | Science, Patients & Strategy

Highlights from the capital markets day 2026

What are the scientific advances, patient needs and strategic opportunities shaping the future of Cereno Scientific?

Watch video >

This highlights video captures key moments from Cereno Scientific’s Capital Markets Day 2026, held on February 5, 2026, where company leadership, clinicians, industry experts and patient representatives shared insights into the company’s mission to pioneer disease-modifying treatments for rare cardiovascular and pulmonary diseases.

The program explored the broader market landscape for rare disease innovation, including growing pharmaceutical industry demand for new therapies as major blockbuster drugs approach loss of exclusivity. With rare diseases increasingly becoming a focus for drug development and licensing activity, innovative biotech companies play a central role in advancing new treatment options.

The event also discussed the strategic role of biotech innovation in developing new therapies and the potential for partnerships with global pharmaceutical companies. Speakers also addressed the clinical reality of pulmonary arterial hypertension (PAH), a rare and life-threatening disease where current treatments mainly aim to slow progression rather than reverse it. A powerful patient perspective highlighted the everyday challenges faced by people living with PAH and the urgent need for therapies that can modify the underlying disease. The event also featured updates on Cereno Scientific’s pipeline, including promising signals from the Phase IIa trial of CS1 and the design of the upcoming Phase IIb study aimed at demonstrating disease modification.

Through these perspectives, the program highlighted Cereno Scientific’s scientific platform based on epigenetic modulation, the experience of its team and advisors, and the company’s strategy to advance innovative therapies addressing significant unmet medical need.